Detalles de la búsqueda
1.
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Lancet;
399(10321): 237-248, 2022 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34953526
2.
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
Clin Infect Dis;
75(1): e783-e791, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34551104
3.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet;
395(10240): 1845-1854, 2020 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32450106
4.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet;
396(10249): 479-488, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702299
5.
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
Emerg Microbes Infect;
13(1): 2281355, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37933089
6.
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Lancet Infect Dis;
23(10): 1143-1152, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37352880
7.
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.
Emerg Microbes Infect;
12(1): 2155251, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36503413
8.
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Lancet Infect Dis;
23(9): 1020-1030, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37216958
9.
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.
Lancet Respir Med;
11(8): 698-708, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37209700
10.
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Lancet Respir Med;
11(7): 613-623, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898400
11.
Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
J Infect;
87(6): 556-570, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37898410
12.
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Lancet Reg Health West Pac;
: 100829, 2023 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37360864
Resultados
1 -
12
de 12
1
Próxima >
>>